TimothyAYapMD

Oncology • Houston, TX

Physician

Join to view full profile

Dr. Yap is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Yap's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

Imperial College London School of MedicineClass of 2002

Certifications & Licensure

TX State Medical License 2018 - 2026
OK State Medical License 2020 - 2021

Clinical Trials

IACS-010759 in Advanced Cancers Start of enrollment: 2017 Nov 13
Completed
Phase 1
Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations Start of enrollment: 2019 Nov 21
ACTIVE_NOT_RECRUITING
PHASE1
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study Start of enrollment: 2020 Jun 30
ACTIVE_NOT_RECRUITING
PHASE1
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors Start of enrollment: 2020 Mar 17
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN Start of enrollment: 2020 Jul 17
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Study of RP-3500, Camonsertib, in Advanced Solid Tumors Start of enrollment: 2020 Jul 22
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Start of enrollment: 2020 Sep 28
Terminated
Phase 1
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies Start of enrollment: 2020 Nov 12
RECRUITING
PHASE1, PHASE2
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial Start of enrollment: 2020 Dec 01
RECRUITING
PHASE1
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL Start of enrollment: 2021 Feb 09
Terminated
Phase 1
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Start of enrollment: 2021 Sep 09
RECRUITING
PHASE1
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations Start of enrollment: 2022 Sep 27
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) Start of enrollment: 2019 Dec 20
ACTIVE_NOT_RECRUITING
PHASE1
Roles: Principal Investigator
Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors Start of enrollment: 2019 Aug 01
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers Start of enrollment: 2024 Jan 30
RECRUITING
PHASE1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial.
Mirella Nardo, Mohamed A Gouda, Matthew J Reilley, Amadeo B Biter, Joann Lim
Journal of Immunotherapy and Precision Oncology. 2025-05-01
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis.
Funda Meric-Bernstam, Aditya Bardia, Paolo Bossi, Giampaolo Bianchini, Frances Gatlin
The Oncologist. 2025-03-10
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study.
Kyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, Jing Gong, Selma Sulovic
Investigational New Drugs. 2025-02-20

Lectures

A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy.
2019 ASCO Annual Meeting - 6/1/2019
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

BridGene Biosciences Announces Dosing of First Patient in Phase 1 Study Evaluating Novel TEAD Inhibitor BGC515 in Advanced Solid TumorsJune 28th, 2024
AACR Annual Meeting 2023: Phase III Immunotherapy Trials Offer Hope for Patients with Lung, Liver, and Biliary Tract CancersMay 4th, 2023
IDEAYA Doses First Patient in Phase L HRD Solid Tumour Therapy TrialApril 19th, 2023
Join now to see all

Grant Support

Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitorsUNIVERSITY OF TX MD ANDERSON CAN CTR2021–2026
Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitorsUNIVERSITY OF TX MD ANDERSON CAN CTR2021–2026

TimothyAYapMD

Dr. Yap is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Viewing the full profile is available to verified healthcare professionals only.